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Prevention of Diabetes in BB/Wor Rats by Intrathymic Islet Injection
Steven B. Koevary and Maureen Blomberg
Department ofCell Biology, University ofMassachusetts Medical School, Worcester, Massachusetts 01655
Abstract
The objective of this study was to determine whether the in-
trathymic injection of islets can prevent the development of
diabetes in BB/Wor rats. Evidence suggests that a failure to
induce islet thymic tolerance may be an etiological factor in the
development of the disease. It was theorized that the introduc-
tion of islets into the thymus might directly induce islet toler-
ance and thus prevent disease. Islets from diabetes-resistant
BB/Wor rats were injected into the thymuses of 23 young dia-
betes-prone BB/Wor rats; 25 sham-operated animals served as
controls. Results showed that 22 of the 25 control rats became
diabetic while only 8 of the 23 experimental rats became dia-
betic (P < 0.0002). The specific lysis of islet cells by spleen
cells from nondiabetic experimental and control rats was com-
parable and less than the lysis induced by spleen cells from
diabetic rats. These data demonstrate that the intrathymic in-
jection of islets into diabetes-prone BB/Wor rats is an effective
method for preventing the development of autoimmune type I
diabetes. (J. Clin. Invest. 1992.89:512-516.) Key words: natu-
ral killer cells * 5Cr release assay * insulin * YAC-1 cells*
tolerance
Introduction
The BB/Wor rat spontaneously develops a diabetic syndrome
similar to that of type I diabetic humans (1-3). These animals
are ketosis prone and require insulin for survival. Though they
are lymphopenic, cell-mediated immune processes have been
implicated in the destruction of their islet cells, specifically
those involving natural killer cells and T lymphocytes (4-7). In
support of a role for T lymphocytes, thymectomy has been
shown to prevent diabetes in BB/Wor rats (8).
Prevention ofBB/Wor rat diabetes by thymectomy focused
attention on the role of the thymus in the etiology of the dis-
ease. Data suggested that the thymus of diabetes-prone (DP)'
rats was defective (9, 10). Georgiou et al. (1 1) demonstrated
that DP thymuses harbored defective macrophage-like antigen
presenting cells (APCs) which were responsible for the activa-
tion of effector lymphocytes capable of destroying islet cells.
Normally, thymic APCs are thought to play an important role
in the generation of selftolerance (12). Since it appears that the
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1. Abbreviations used in this paper: APCs, antigen-presenting cells; DP,
diabetes prone; DR, diabetes resistant.
development of diabetes in the BB/Wor rat may be due to an
abnormal bone marrow-derived thymic APC, it was assumed
that some defect in self-tolerance induction may be involved in
disease development.
The objective of this study was to determine whether bol-
stering immunological tolerance to islet antigens can prevent
the development of autoimmune diabetes in the rat. Injection
of islets intrathymically might be one mechanism by which the
activity ofthymic APCs, vis-a-vis their role in establishing islet
tolerance, could be enhanced. Ihm et al. (13) suggested that
islets from rats of the age at which self tolerance is normally
induced, i.e., neonates, lacked certain antigenic determinants,
which could also explain the lack of islet tolerance in adult
BB/Wor rats. Intrathymic injection of adult islets containing
these antigens could help to reestablish islet tolerance. An im-
portant precedent for this study comes from the work ofPosselt
et al. (14), who successfully induced donor-specific unrespon-
siveness by transplanting islets intrathymically into two-month
old, streptozotocin-induced diabetic allogeneic recipients.
Methods
Animals. BB/Wor rats were obtained from the University ofMassachu-
setts breeding facility. 48 DP rats were used in this study. In addition,
diabetes-resistant (DR) rats, used as a source of islet cells, and a small
number of acutely diabetic BB/Wor rats (within five days of onset)
were also used. Diabetes develops in DP animals at a mean (±SE) age of
78.4±0.5 d; the frequency of disease is between 80 and 90% (15). All
DP rats used in this study were monitored for the presence of urine
glucose starting at 50 days of age, using Testape (Eli Lilly & Co., In-
dianapolis, IN).
Intrathymic injection of islets. Islets were isolated from 3-mo old
DR rats as previously described (5). Before injection, the islets were
irradiated with 1,800 rads (see Discussion). The cells were then washed
twice and resuspended in serum-free RPMI medium in a siliconized
tube. The yield from one to two rats (300-600 islets) was injected into
each recipient thymus in a volume of 0.1 ml. Under ketamine/ropum
anesthesia (0.1 ml/100 g body wt), the lower ventral neck and supra-
sternal regions of recipient rats were exposed. The superficial muscles
as well as the upper few millimeters of the sternum were cut through,
exposing the thymus. The islets were injected into the thymus using a
1-cc syringe with a 27G needle. The wound was sealed using surgical
staples. 23 randomized DP recipients (mean±SE age was 32±0.3 d)
were injected with DR islets, while 25 age matched, randomized DP
rats were sham operated and had their thymuses injected with media
alone.
The pancreatic and intrathymic islets of all nondiabetic rats re-
maining at the end of the study (150 days of age) were fixed in Bouin's
solution, postfixed in 10% formalin, and embedded in paraffin. 4-um
sections were cut (at three different levels in the thymuses) and stained
with hematoxylin and eosin, while adjacent sections were immunocyto-
chemically stained for insulin and counterstained with hematoxylin.
Islet cell cytotoxicity assay. Spleen cells from nondiabetic DP rats
remaining at the end ofthis study were examined for their ability to lyse
DR rat islet target cells. Spleen cells from acutely diabetic and DR rats
served as positive and negative controls, respectively. The assay in-
volved the use of 5"Cr and has been described in detail elsewhere (5).
The media used was RPMI supplemented with 10% heat inactivated
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fetal calf serum (Gibco Laboratories, Grand Island, NY), 5 mM gluta-
mine, 5 x 10' M fl-mercaptoethanol, 100 U/ml penicillin, and 100
Ag/ml streptomycin.
Spleen cells (10'/ml) were pipetted in quadruplicate into round
bottomed wells in a 96-well plate (Costar Corp., Cambridge, MA) in a
volume of 100 Ml. Target islet cells were isolated from DR rats and
dissociated as previously described (5). Islet cells (200,000 cells/ml)
which had previously been labelled with 5"Cr (200 1 of5"Cr-as sodium
chromate for 1 h at 370C, followed by three washes; sp act 400-1,200
Ci/g; New England Nuclear, Boston, MA) were then added into the
wells in a volume of 100 Ml(20,000 target cells/well; effectorntarget ratio
of 50:1). The plates were centrifuged for 1 min at 700 rpm and incu-
bated for 16 h in 5% CO2 in air at 370C. Supernatants (100 M1) were
then removed from each well and counted in a gamma counter (Pack-
ard Instrument Co., Inc., Meriden, CT). The percent specific lysis was
calculated using the following formula:
% Specific lysis
Experimental(cpm) - Spontaneous release(cpm) x 100
Total(cpm) - Spontaneous release(cpm)
Total counts were determined at the beginning of the assay by
counting 0.1-ml aliquots of 5"Cr-labelled target cells. Spontaneous re-
lease of 5'Cr from target cells incubated in the absence of spleen cells
was also determined. In addition to islet cell targets, YAC-l target cells
were also used in this assay. YAC-l cells are natural killer-sensitive
mouse leukemia virus-induced, T lymphoma cells (16). These cells
were labelled and otherwise handled in the same way as islet cell targets.
FACSO analysis oflymphocyte subsets. Lymphocyte subsets in the
spleens of nondiabetic experimental and control DP rats were analyzed
on the FACS6. Double label analyses were performed using monoclo-
nal antibodies OX 19 and OX8. OX 19 reacts with all T cells. Classical
cytotoxic/suppressor T cells are contained in the OX8+/OXl9+ lym-
phocyte subset while natural killer cells are contained in the OX8+/
OX 19- lymphocyte subset. 5 X 106 spleen cells were incubated with
200 Ml ofmouse monoclonal OX8 (30 Mg/ml; Bioproducts for Science,
Inc., Indianapolis, IN) for 30 min, washed twice, and incubated with
200 Al of fluorescein-conjugated goat anti-mouse IgG (30 Mg/ml: Or-
ganon Teknika/Cappel, Rockville, MD) for 30 min. This secondary
antibody does not cross-react with rat IgG. The cells were washed twice,
incubated with 200 Ml of mouse IgG (200 Ag/ml; Organon Teknika/
Cappel) to block any remaining active sites on the secondary antibody,
washed twice, and incubated with 200 Ml of OX19-biotin (30 Mg/ml:
Bioproducts for Science; biotinylation performed by Molecular Probes,
Eugene, OR) for 30 min. After OX19-biotin incubation, the cells were
washed twice and incubated with 100 Ml of streptavidin-R-phycoer-
ythrin conjugate (20 Mg/ml; Molecular Probes) for 30 min. All incuba-
tions and washes were performed in PBS supplemented with 0.5% BSA
(Sigma Chemical Co., St. Louis, MO) at 4°C. Background fluorescence
was determined by controls in which normal mouse IgG was substi-
tuted for one of the primary antibodies (OX8 or OX 19). After this
double labelling procedure, cells were fixed in 4% paraformaldehyde
for 7 min at 4°C, washed twice, and resuspended in MEM media sup-
plemented with 10% heat inactivated fetal calfserum. Fixed cells were
analyzed (2 25,000 cells/sample) using a FACSStar Plus" (Becton
Dickinson & Co., Mountain View, CA).
Statistics. The Student's t test was used to determine significance
levels for the cytotoxicity and FACS0 data. The effects of intrathymic
islet injections on the incidence ofdiabetes was evaluated using Fisher's
exact test (17).
Results
Effects ofintrathymic islet injection on diabetes incidence
The intrathymic injection of islets into DP rats significantly
reduced (P < 0.0002) their incidence of diabetes. These results
are shown in Table I. 88% (22 of 25) ofcontrol, sham-operated
Table L Effects ofIntrathymic Islet Injections on the Development
ofDiabetes in the BBRWor Rat
Treatment n Number diabetic Percent diabetic
Sham operated* 25 22 88
Intrathymic islets 23 8* 35
* Thymuses injected with vehicle. $ Significantly fewer than sham
operated, P < 0.0002.
rats became diabetic by 150 days of age, while only 35% (8 of
23) experimental rats developed disease. The age of onset of
diabetes in animals that did become diabetic was similar in
both groups (mean±SE was 83.6±4.5 for the controls and
78.4±5.2 for the experimentals).
Morphological analysis of the thymuses of nondiabetic ex-
perimental animals revealed the presence of islet tissue con-
taining well granulated beta cells (Fig. 1), though fewer islets
were found than expected, considering the numbers injected.
When present, intact islets were generally observed within con-
nective tissue septa; distorted islets and large and small groups
of individual islet cells were present within the thymic paren-
chyma. Analysis of 5 of the 8 thymuses of experimental ani-
mals that became diabetic revealed a pattern of islet distribu-
tion similar to that seen in protected animals. Examination of
the pancreata of nondiabetic animals remaining at the end of
the study revealed an absence ofautoimmune insulitis in both
experimental and control groups. However, three experimental
and two control pancreata displayed periductular and perivas-
cular inflammation.
5lCr-release assay
Spleen cells from a number of nondiabetic experimental (n
= 10) and control (n = 3) DP rats were analyzed for their ability
to lyse islet and YAC- 1 cell targets. Results are shown in Table
II. There were no significant differences between the level of
killing of islet or YAC-1 cells between experimental and con-
trol rats. Lysis ofislet cells by spleen cells from both experimen-
tal nondiabetic (mean±SE was 15.9±1.6) and control nondia-
betic (16.4±1.1) animals was significantly lower (P < 0.001)
than lysis by spleen cells from diabetic rats (26.4±1.4; n = 4).
YAC-1 lysis by spleen cells from experimental nondiabetic
(60±1.6) and control (54.5±2.5) animals were insignificantly
different from lysis by spleen cells from diabetic rats (59.4±1.5;
n = 4).
FACS®
The mean±SE concentrations ofOXl9+ and OX8+/OX19-
cells were 1 1.0±0.5% and 18.0±1.0%, respectively, in the exper-
imental group (n = 10) and 9.4±0.7% and 14.5±3.0%, respec-
tively, in the control group (n = 3) (not significant). The
mean±SE concentrations ofOX8+/OX 19+ cells were 1.2±0.1
in the experimental group and 0.9±0.1% in the control group
(P < 0.02 compared to experimental group).
Discussion
The objective of this study was to determine whether the in-
trathymic injection of islets into DP rats can prevent the devel-
opment of disease in the BB/Wor rat. Our results suggest that
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Table I. 5"Cr Releasefrom DR Islets and YAC-1 Cells Incubated
with Spleen Cellsfrom Nondiabetic Experimental
and Control Rats
Target Spleen cell donor Percent specific lysis (mean±SE)
Islet Experimental nondiabetics 15.9±1.6
Control nondiabetics 16.4±1.1
YAC-1 Experimental nondiabetics 60.0±1.6
Control nondiabetics 54.5±2.5
All experimental and control values within a target group were statis-
tically insignificantly different from each other. Spleen cells from
acutely diabetic BB/Wor rats and DR rats served as positive and neg-
ative controls for this assay. Lysis of islet and YAC- I cells by acutely
diabetic spleen cells was 26.4±1.4% and 59.4±1.5%, respectively,
while DR lysis was 6.5% and 31.5%, respectively.
autoimmune type I diabetes can in fact be prevented using this
methodology.
Morphological examination of the thymuses of protected
animals revealed relatively few islets, considering the number
injected, in spite ofthe fact that three thymic levels were exam-
ined. Intact islets were observed only within thymic connective
tissue septa. Islet cells that were localized within the lympho-
cyte parenchyma of the thymus were present as small, isolated
clusters of few cells and not as intact islets. Most of these cells
seemed to be present in or near the thymic medulla. What
might be speculated from these observations is that islets do not
survive well in the thymic cortex, perhaps because thymic mac-
rophages and lymphocytes have eliminated them in the process
of presenting them to maturing T cells. A time course study of
the disposition ofintrathymic islets should help to clarify these
findings. It is not immediately clearwhy all ofthe experimental
animals were not protected from the development of diabetes,
since they all appeared to have the same pattern of islet distri-
bution within their thymuses. A quantitative time course analy-
sis of the fate of intrathymic islets should also help to answer
this question.
Recall that the islets were first irradiated before their in-
trathymic injection. This was done in an attempt to interfere
with their ability to release insulin in response to glucose. Got-
fredsen et al. (18) and Like (19) suggested that insulin injec-
tions could prevent the development of BB rat diabetes by di-
minishing the activity and size, and consequently the immuno-
genicity, of their islets. Though the possibility seemed remote
that the levels of insulin released from intrathymic islets could
reach high enough levels to reduce the activity ofthe pancreatic
islets, we thought we would try to eliminate this possibility
altogether by the simple method of irradiation. Our data (not
shown) suggested that irradiation had no effect on the inhibi-
tion of islet insulin secretion. It should be emphasized, how-
ever, that the possibility that insulin, released from intrathymic
islets, could play a role in diabetes prevention is considered
very remote. Data from Hegre et al. showed that transplanta-
tion of islets into DP rats before 60 days ofage did not appear to
affect their incidence ofdiabetes (20). In addition, subjectively,
the size of the pancreatic islets of protected animals appeared
similar to the size ofthe islets in the pancreata ofcontrol, nondi-
abetic rats; thus a "shutting down" of the pancreatic islets did
not seem to be occurring. Successful protection from disease by
injecting fixed islets intrathymically would unequivocally lay
this question to rest.
Experimental nondiabetic rats remaining at the end of this
study exhibited a similar capacity to lyse islet target cells in
vitro compared to control rats. This lysis was less than that
exhibited by spleen cells from acutely diabetic rats but greater
than the lysis by DR spleen cells. It may be theorized that the
intrathymic injection of islets in DP rats prevented the aug-
mentation of splenic antiislet immunoreactivity to that seen in
diabetic animals and thus prevented the development of dis-
ease. Spleen cell lysis ofYAC- 1 cells was similar in experimen-
tal and control groups and comparable to that exhibited by
spleen cells from diabetic rats. The fact that DP spleen cell lysis
of YAC- 1 cells was comparable to diabetic spleen cell lysis has
been previously reported (21, 22).
The extremely slight, but statistically significant, increase in
the number of OX8+/OX 19+ cells is probably not biologically
significant, though it is tempting to speculate that it represents
an increase in the number of islet suppressor cells. Interest-
ingly, Posselt et al. (14) similarly revealed no differences in
lymphocyte populations between thymic islet allograft recipi-
ents and normal controls or hosts oflong-standing intratesticu-
lar or renal subcapsular allografts. It is clear that changes in
lymphocyte subsets do not necessarily correlate with changes
in the disease state. Thus, Thomas et al. (23) failed to show
changes in lymphocyte subsets in DR rats that developed dia-
betes after polyinosinic polycytidilic acid treatment, and Ros-
sini et al. (24) showed no changes in lymphocyte subsets after
total lymphoid irradiation in diabetes-protected animals.
Changes in the activity of lymphocytes within a given subset
may have accounted for these, and our present, findings.
Evidence suggests that a failure to induce islet tolerance
may be an etiological factor in the development of diabetes.
This evidence includes the data of Georgiou et al. (11), who
showed that thymic APCs in DP rats may be defective in their
ability to establish islet tolerance. In all likelihood, this lack of
tolerance induction manifests itselfby the absence ofcells capa-
ble of suppressing islet effectors. Furthermore, the data of Ihm
et al. (13) suggested that islets from rats of the age at which self
tolerance is normally induced, i.e., neonates, lacked certain
antigenic determinants, which could explain the lack of islet
tolerance in adult DP rats. In support of Ihm's data, Buschard
et al. (25) reported that diabetes in BB rats can be prevented by
the neonatal stimulation of beta cells. This procedure was
thought to induce or enhance antigen expression on the beta
cells, which facilitated the immune system's ability to develop
beta cell tolerance (26).
As mentioned earlier, Posselt et al. (14) were successful in
inducing donor-specific unresponsiveness by transplanting is-
lets intrathymically into two-month old streptozotocin-in-
duced diabetic allogeneic recipients. Not only were the intra-
thymic islets not rejected, but once tolerance was achieved,
islets transplanted to extrathymic sites were also protected. Our
study is significant since it shows that not only rejection but
specific autoimmune attack can be prevented by intrathymic
islet injection. Recall that in a diabetic recipient of an identical
twin's pancreatic graft, a specific autoimmune attack was re-
sponsible for the destruction of the beta cells in that graft soon
after transplantation (27). While it is tempting to attribute the
findings presented here to the induction of specific islet toler-
ance, such a conclusion awaits further experimentation.
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